{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T02:51:24Z","timestamp":1783651884639,"version":"3.55.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T00:00:00Z","timestamp":1693958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T00:00:00Z","timestamp":1693958400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005739","name":"Universidad Nacional Aut\u00f3noma de M\u00e9xico","doi-asserted-by":"publisher","award":["405PC"],"award-info":[{"award-number":["405PC"]}],"id":[{"id":"10.13039\/501100005739","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005739","name":"Universidad Nacional Aut\u00f3noma de M\u00e9xico","doi-asserted-by":"publisher","award":["405PC"],"award-info":[{"award-number":["405PC"]}],"id":[{"id":"10.13039\/501100005739","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005739","name":"Universidad Nacional Aut\u00f3noma de M\u00e9xico","doi-asserted-by":"publisher","award":["405PC"],"award-info":[{"award-number":["405PC"]}],"id":[{"id":"10.13039\/501100005739","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005739","name":"Universidad Nacional Aut\u00f3noma de M\u00e9xico","doi-asserted-by":"publisher","award":["405PC"],"award-info":[{"award-number":["405PC"]}],"id":[{"id":"10.13039\/501100005739","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005739","name":"Universidad Nacional Aut\u00f3noma de M\u00e9xico","doi-asserted-by":"publisher","award":["405PC"],"award-info":[{"award-number":["405PC"]}],"id":[{"id":"10.13039\/501100005739","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005739","name":"Universidad Nacional Aut\u00f3noma de M\u00e9xico","doi-asserted-by":"publisher","award":["405PC"],"award-info":[{"award-number":["405PC"]}],"id":[{"id":"10.13039\/501100005739","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003141","name":"Consejo Nacional de Ciencia y Tecnolog\u00eda","doi-asserted-by":"publisher","award":["247164,289568, A1-S-9620B"],"award-info":[{"award-number":["247164,289568, A1-S-9620B"]}],"id":[{"id":"10.13039\/501100003141","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003141","name":"Consejo Nacional de Ciencia y Tecnolog\u00eda","doi-asserted-by":"publisher","award":["247164,289568, A1-S-9620B"],"award-info":[{"award-number":["247164,289568, A1-S-9620B"]}],"id":[{"id":"10.13039\/501100003141","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003141","name":"Consejo Nacional de Ciencia y Tecnolog\u00eda","doi-asserted-by":"publisher","award":["247164,289568, A1-S-9620B"],"award-info":[{"award-number":["247164,289568, A1-S-9620B"]}],"id":[{"id":"10.13039\/501100003141","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003141","name":"Consejo Nacional de Ciencia y Tecnolog\u00eda","doi-asserted-by":"publisher","award":["247164, 289568, and A1-S-9620B"],"award-info":[{"award-number":["247164, 289568, and A1-S-9620B"]}],"id":[{"id":"10.13039\/501100003141","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003141","name":"Consejo Nacional de Ciencia y Tecnolog\u00eda","doi-asserted-by":"publisher","award":["247164, 289568, and A1-S-9620B"],"award-info":[{"award-number":["247164, 289568, and A1-S-9620B"]}],"id":[{"id":"10.13039\/501100003141","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003141","name":"Consejo Nacional de Ciencia y Tecnolog\u00eda","doi-asserted-by":"publisher","award":["247164, 289568, and A1-S-9620B"],"award-info":[{"award-number":["247164, 289568, and A1-S-9620B"]}],"id":[{"id":"10.13039\/501100003141","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003141","name":"Consejo Nacional de Ciencia y Tecnolog\u00eda","doi-asserted-by":"publisher","award":["247164,289568, A1-S-9620B"],"award-info":[{"award-number":["247164,289568, A1-S-9620B"]}],"id":[{"id":"10.13039\/501100003141","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background\/Objective<\/jats:title>\n                <jats:p>The prokinetic levosulpiride elevates vasoinhibin levels in the vitreous of patients with proliferative diabetic retinopathy (PDR) suggesting clinical benefits due to the anti-vasopermeability and anti-angiogenic properties of vasoinhibin. We investigated the biological activity of levosulpiride in centre-involving diabetic macular oedema (DME).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Patients\/Methods<\/jats:title>\n                <jats:p>Prospective, randomized, double-blinded, dual-centre, phase 2 trial in patients with centre-involving DME orally treated with placebo (<jats:italic>n<\/jats:italic>\u2009=\u200917) or levosulpiride (<jats:italic>n<\/jats:italic>\u2009=\u200917) for 8 weeks or in patients with PDR undergoing elective pars plana vitrectomy and receiving placebo (<jats:italic>n<\/jats:italic>\u2009=\u200918) or levosulpiride (<jats:italic>n<\/jats:italic>\u2009=\u200918) orally for the 1 week before vitrectomy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Levosulpiride improved changes from baseline in best-corrected visual acuity (<jats:italic>p<\/jats:italic>\u2009\u2264\u20090.037), central foveal thickness (CFT, <jats:italic>p<\/jats:italic>\u2009\u2264\u20090.013), and mean macular volume (MMV, <jats:italic>p<\/jats:italic>\u2009\u2264\u20090.002) at weeks 4, 6, and 8 compared to placebo. At 8 weeks, the proportion of eyes gaining \u22655 ETDRS letters at 4\u2009m (41% vs. 28%), losing \u226521\u2009\u03bcm in CFT (55% vs. 28%), and dropping \u22650.06\u2009mm<jats:sup>3<\/jats:sup> in MMV (65% vs. 29%) was higher after levosulpiride than placebo. The overall grading of visual and structural parameters improved with levosulpiride (<jats:italic>p<\/jats:italic>\u2009=\u20090.029). Levosulpiride reduced VEGF (<jats:italic>p<\/jats:italic>\u2009=\u20090.025) and PlGF (<jats:italic>p<\/jats:italic>\u2009=\u20090.008) levels in the vitreous of PDR patients. No significant adverse side-effects were detected.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Oral levosulpiride for 8 weeks improved visual and structural outcomes in patients with centre-involving DME by mechanisms that may include intraocular upregulation of vasoinhibin and downregulation of VEGF and PlGF. Larger clinical trials evaluating long-term efficacy and safety are warranted.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1038\/s41433-023-02715-5","type":"journal-article","created":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T12:01:32Z","timestamp":1694001692000},"page":"520-528","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Levosulpiride for the treatment of diabetic macular oedema: a phase 2 randomized clinical trial"],"prefix":"10.1038","volume":"38","author":[{"given":"Carlos D.","family":"N\u00fa\u00f1ez-Amaro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elva","family":"Ad\u00e1n-Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma. Ludivina","family":"Robles-Osorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Garc\u00eda-Franco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlon","family":"Garc\u00eda-Roa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolanda","family":"Villalpando-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulina","family":"Ram\u00edrez-Neria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nayeli","family":"Pineiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3853-1934","authenticated-orcid":false,"given":"Juan Fernando","family":"Rubio-Mijangos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Ram\u00edrez-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lourdes","family":"Siqueiros-M\u00e1rquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nundehui","family":"D\u00edaz-Lezama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellery","family":"L\u00f3pez-Star","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Bertsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonzalo","family":"Mar\u00ednez de la Escalera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1989-8645","authenticated-orcid":false,"given":"Jakob","family":"Triebel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7670-6718","authenticated-orcid":false,"given":"Carmen","family":"Clapp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,6]]},"reference":[{"key":"2715_CR1","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1097\/ICU.0000000000000424","volume":"28","author":"S Cai","year":"2017","unstructured":"Cai S, Bressler NM. Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema: recent clinically relevant findings from DRCR.net Protocol T. Curr Opin Ophthalmol. 2017;28:636\u201343.","journal-title":"Curr Opin Ophthalmol"},{"key":"2715_CR2","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s11892-019-1188-4","volume":"19","author":"EJ Kim","year":"2019","unstructured":"Kim EJ, Lin WV, Rodriguez SM, Chen A, Loya A, Weng CY. Treatment of diabetic macular edema. Curr Diab Rep. 2019;19:68.","journal-title":"Curr Diab Rep"},{"key":"2715_CR3","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1152\/physrev.00024.2009","volume":"89","author":"C Clapp","year":"2009","unstructured":"Clapp C, Thebault S, Jeziorski MC, Mart\u00ednez De La Escalera G. Peptide hormone regulation of angiogenesis. Physiol Rev. 2009;89:1177\u2013215.","journal-title":"Physiol Rev"},{"key":"2715_CR4","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/978-3-319-12114-7_4","volume":"846","author":"C Clapp","year":"2015","unstructured":"Clapp C, Thebault S, Macotela Y, Moreno-Carranza B, Triebel J, Mart\u00ednez de la Escalera G. Regulation of blood vessels by prolactin and vasoinhibins. Adv Exp Med Biol. 2015;846:83\u201395.","journal-title":"Adv Exp Med Biol"},{"key":"2715_CR5","doi-asserted-by":"publisher","first-page":"R1193","DOI":"10.1152\/ajpregu.00256.2015","volume":"309","author":"J Triebel","year":"2015","unstructured":"Triebel J, Bertsch T, Bollheimer C, Rios-Barrera D, Pearce CF, H\u00fcfner M, et al. Principles of the prolactin\/vasoinhibin axis. Am J Physiol Regul Integr Comp Physiol. 2015;309:R1193\u2013203.","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"2715_CR6","first-page":"2498","volume":"40","author":"Z Due\u00f1as","year":"1999","unstructured":"Due\u00f1as Z, Torner L, Corbacho AM, Ochoa A, Guti\u00e9rrez\u2013Ospina G, L\u00f3pez\u2013Barrera F, et al. Inhibition of rat corneal angiogenesis by 16-kDa prolactin and by endogenous prolactin-like molecules. Invest Ophthalmol Vis Sci. 1999;40:2498\u2013505.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2715_CR7","doi-asserted-by":"publisher","first-page":"2947","DOI":"10.1167\/iovs.05-0173","volume":"46","author":"J Aranda","year":"2005","unstructured":"Aranda J, Rivera JC, Jeziorski MC, Riesgo-Escovar J, Nava G, L\u00f3pez-Barrera F, et al. Prolactins are natural inhibitors of angiogenesis in the retina. Invest Ophthalmol Vis Sci. 2005;46:2947\u201353.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2715_CR8","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1167\/iovs.03-1346","volume":"45","author":"Z Due\u00f1as","year":"2004","unstructured":"Due\u00f1as Z, Rivera JC, Quir\u00f3z-Mercado H, Aranda J, Macotela Y, Montes de Oca P, et al. Prolactin in eyes of patients with retinopathy of prematurity: implications for vascular regression. Invest Ophthalmol Vis Sci. 2004;45:2049\u201355.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2715_CR9","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/pr.2016.241","volume":"81","author":"LC Zepeda-Romero","year":"2017","unstructured":"Zepeda-Romero LC, Vazquez-Membrillo M, Adan-Castro E, Gomez-Aguayo F, Gutierrez-Padilla JA, Angulo-Castellanos E, et al. Higher prolactin and vasoinhibin serum levels associated with incidence and progression of retinopathy of prematurity. Pediatr Res. 2017;81:473\u20139.","journal-title":"Pediatr Res"},{"key":"2715_CR10","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1530\/EJE-09-0130","volume":"161","author":"J Triebel","year":"2009","unstructured":"Triebel J, Huefner M, Ramadori G. Investigation of prolactin-related vasoinhibin in sera from patients with diabetic retinopathy. Eur J Endocrinol. 2009;161:345\u201353.","journal-title":"Eur J Endocrinol"},{"key":"2715_CR11","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1167\/iovs.03-1001","volume":"45","author":"H Pan","year":"2004","unstructured":"Pan H, Nguyen NQ, Yoshida H, Bentzien F, Shaw LC, Rentier-Delrue F, et al. Molecular targeting of antiangiogenic factor 16K hPRL inhibits oxygen-induced retinopathy in mice. Invest Ophthalmol Vis Sci. 2004;45:2413\u20139.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2715_CR12","first-page":"2291","volume":"118","author":"C Garc\u00eda","year":"2008","unstructured":"Garc\u00eda C, Aranda J, Arnold E, Th\u00e9bault S, Macotela Y, L\u00f3pez-Casillas F, et al. Vasoinhibins prevent retinal vasopermeability associated with diabetic retinopathy in rats via protein phosphatase 2A-dependent eNOS inactivation. J Clin Invest. 2008;118:2291\u2013300.","journal-title":"J Clin Invest"},{"key":"2715_CR13","doi-asserted-by":"publisher","first-page":"8944","DOI":"10.1167\/iovs.11-8190","volume":"52","author":"M Ram\u00edrez","year":"2011","unstructured":"Ram\u00edrez M, Wu Z, Moreno-Carranza B, Jeziorski MC, Arnold E, D\u00edaz-Lezama N, et al. Vasoinhibin gene transfer by adenoassociated virus type 2 protects against VEGF- and diabetes-induced retinal vasopermeability. Invest Ophthalmol Vis Sci. 2011;52:8944\u201350.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2715_CR14","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/labinvest.2015.135","volume":"96","author":"N D\u00edaz-Lezama","year":"2016","unstructured":"D\u00edaz-Lezama N, Wu Z, Ad\u00e1n-Castro E, Arnold E, V\u00e1zquez-Membrillo M, Arredondo-Zamarripa D, et al. Diabetes enhances the efficacy of AAV2 vectors in the retina: therapeutic effect of AAV2 encoding vasoinhibin and soluble VEGF receptor 1. Lab Investig. 2016;96:283\u201395.","journal-title":"Lab Investig"},{"key":"2715_CR15","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.2337\/db10-0873","volume":"59","author":"E Arnold","year":"2010","unstructured":"Arnold E, Rivera JC, Thebault S, Moreno-P\u00e1ramo D, Quiroz-Mercado H, Quintanar-St\u00e9phano A, et al. High levels of serum prolactin protect against diabetic retinopathy by increasing ocular vasoinhibins. Diabetes. 2010;59:3192\u20137.","journal-title":"Diabetes"},{"key":"2715_CR16","doi-asserted-by":"publisher","first-page":"242","DOI":"10.3389\/fendo.2018.00242","volume":"9","author":"ML Robles-Osorio","year":"2018","unstructured":"Robles-Osorio ML, Garc\u00eda-Franco R, N\u00fa\u00f1ez-Amaro CD, Mira-Lorenzo X, Ram\u00edrez-Neria P, Hern\u00e1ndez W, et al. Basis and design of a randomized clinical trial to evaluate the effect of levosulpiride on retinal alterations in patients with diabetic retinopathy and diabetic macular edema. Front Endocrinol. 2018;9:242.","journal-title":"Front Endocrinol"},{"key":"2715_CR17","first-page":"1034","volume":"2","author":"I Ratnani","year":"2015","unstructured":"Ratnani I, Panchal B, Gandhi R, Vala A, Mandal K. Role of levosulpiride in the management of functional dyspepsia. J Fam Med. 2015;2:1034.","journal-title":"J Fam Med"},{"key":"2715_CR18","doi-asserted-by":"publisher","first-page":"355","DOI":"10.4103\/ijem.IJEM_555_16","volume":"21","author":"MS Kuchay","year":"2017","unstructured":"Kuchay MS, Mithal A. Levosulpiride and serum prolactin levels. Indian J Endocrinol Metab. 2017;21:355\u20138.","journal-title":"Indian J Endocrinol Metab"},{"key":"2715_CR19","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1167\/tvst.9.9.27","volume":"9","author":"CD Nu\u00f1ez-Amaro","year":"2020","unstructured":"Nu\u00f1ez-Amaro CD, Moreno-Vega AI, Adan-Castro E, Zamora M, Garcia-Franco R, Ramirez-Neria P, et al. Levosulpiride increases the levels of prolactin and antiangiogenic vasoinhibin in the vitreous of patients with proliferative diabetic retinopathy. Transl Vis Sci Technol. 2020;9:27.","journal-title":"Transl Vis Sci Technol"},{"key":"2715_CR20","doi-asserted-by":"publisher","first-page":"e13091","DOI":"10.1111\/jne.13091","volume":"34","author":"E Ad\u00e1n-Castro","year":"2022","unstructured":"Ad\u00e1n-Castro E, Siqueiros-M\u00e1rquez L, Ram\u00edrez-Hern\u00e1ndez G, D\u00edaz-Lezama N, Ru\u00edz-Herrera X, N\u00fa\u00f1ez FF, et al. Sulpiride-induced hyperprolactinaemia increases retinal vasoinhibin and protects against diabetic retinopathy in rats. J Neuroendocrinol. 2022;34:e13091.","journal-title":"J Neuroendocrinol"},{"key":"2715_CR21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12886-016-0396-9","volume":"17","author":"Y Minami","year":"2017","unstructured":"Minami Y, Nagaoka T, Ishibazawa A, Yoshida A. Short-term effects of intravitreal ranibizumab therapy on diabetic macular edema. BMC Ophthalmol. 2017;17:1\u20136.","journal-title":"BMC Ophthalmol"},{"key":"2715_CR22","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ajo.2016.09.012","volume":"172","author":"VH Gonzalez","year":"2016","unstructured":"Gonzalez VH, Campbell J, Holekamp NM, Kiss S, Loewenstein A, Augustin AJ, et al. Early and long-term responses to anti-vascular endothelial growth factor therapy in diabetic macular edema: analysis of protocol I data. Am J Ophthalmol. 2016;172:72\u20139.","journal-title":"Am J Ophthalmol"},{"key":"2715_CR23","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1056\/NEJM199412013312203","volume":"331","author":"LP Aiello","year":"1994","unstructured":"Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331:1480\u20137.","journal-title":"N Engl J Med"},{"key":"2715_CR24","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/eye.2016.246","volume":"31","author":"E Al Kahtani","year":"2017","unstructured":"Al Kahtani E, Xu Z, Al Rashaed S, Wu L, Mahale A, Tian J, et al. Vitreous levels of placental growth factor correlate with activity of proliferative diabetic retinopathy and are not influenced by bevacizumab treatment. Eye. 2017;31:529\u201336.","journal-title":"Eye"},{"key":"2715_CR25","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1056\/NEJMoa1414264","volume":"372","author":"J Wells","year":"2015","unstructured":"Wells J, Glassman A, Ayala A, Jampol L, Aiello L, Antoszyk A, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372:1193\u2013203.","journal-title":"N Engl J Med"},{"key":"2715_CR26","doi-asserted-by":"crossref","unstructured":"Ortiz G, Ledesma-Colunga MG, Wu Z, Garc\u00eda-Rodrigo JF, Adan N, De La Escalera GM, et al. Vasoinhibin reduces joint inflammation, bone loss, and the angiogenesis and vasopermeability of the pannus in murine antigen-induced arthritis. Lab Investig. 2020;100:1068\u201379.","DOI":"10.1038\/s41374-020-0432-5"},{"key":"2715_CR27","doi-asserted-by":"publisher","first-page":"2953","DOI":"10.1167\/iovs.08-2870","volume":"50","author":"H Shimada","year":"2009","unstructured":"Shimada H, Akaza E, Yuzawa M, Kawashima M. Concentration gradient of vascular endothelial growth factor in the vitreous of eyes with diabetic macular edema. Invest Ophthalmol Vis Sci. 2009;50:2953\u20135.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2715_CR28","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1111\/aos.13325","volume":"96","author":"QD Nguyen","year":"2018","unstructured":"Nguyen QD, De Falco S, Behar-Cohen F, Lam WC, Li X, Reichhart N, et al. Placental growth factor and its potential role in diabetic retinopathy and other ocular neovascular diseases. Acta Ophthalmol. 2018;96:e1\u20139.","journal-title":"Acta Ophthalmol"},{"key":"2715_CR29","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/eye.2013.107","volume":"27","author":"KG Falavarjani","year":"2013","unstructured":"Falavarjani KG, Nguyen QD. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye. 2013;27:787.","journal-title":"Eye"},{"key":"2715_CR30","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1001\/jama.2019.5790","volume":"321","author":"CW Baker","year":"2019","unstructured":"Baker CW, Glassman AR, Beaulieu WT, Antoszyk AN, Browning DJ, Chalam KV, et al. Effect of initial management with aflibercept vs laser photocoagulation vs observation on vision loss among patients with diabetic macular edema involving the center of the macula and good visual acuity: a randomized clinical trial. JAMA. 2019;321:1880.","journal-title":"JAMA"},{"key":"2715_CR31","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1001\/jamaophthalmol.2021.0013","volume":"139","author":"MA Grassi","year":"2021","unstructured":"Grassi MA. What is just the right amount of anti-vascular endothelial growth factor treatment for diabetic macular edema?: protocol V and the Goldilocks principle. JAMA Ophthalmol. 2021;139:381\u20132.","journal-title":"JAMA Ophthalmol"},{"key":"2715_CR32","doi-asserted-by":"publisher","first-page":"393","DOI":"10.2147\/OPTH.S128509","volume":"11","author":"KJ Blinder","year":"2017","unstructured":"Blinder KJ, Dugel PU, Chen S, Jumper JM, Walt JG, Hollander DA, et al. Anti-VEGF treatment of diabetic macular edema in clinical practice: effectiveness and patterns of use (ECHO Study Report 1). Clin Ophthalmol. 2017;11:393\u2013401.","journal-title":"Clin Ophthalmol"},{"key":"2715_CR33","first-page":"1989","volume":"90","author":"C Mansi","year":"1995","unstructured":"Mansi C, Savarino V, Vigneri S, Perilli D, Melga P, Sciab\u00e0 L, et al. Gastrokinetic effects of levosulpiride in dyspeptic patients with diabetic gastroparesis. Am J Gastroenterol. 1995;90:1989\u201393.","journal-title":"Am J Gastroenterol"},{"key":"2715_CR34","doi-asserted-by":"crossref","unstructured":"Lozano R, Peralta Concha MG, Montealegre A, de Leon L, Ortiz Villalba J, Esteban HL, et al. Effectiveness and safety of levosulpiride in the treatment of dysmotility-like functional dyspepsia. Ther Clin Risk Manag. 2007;3:149\u201355.","DOI":"10.2147\/tcrm.2007.3.1.149"},{"key":"2715_CR35","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2337\/diacare.20.1.55","volume":"20","author":"P Melga","year":"1997","unstructured":"Melga P, Mansi C, Ciuchi E, Giusti R, Sciab\u00e0 L, Prando R. Chronic administration of levosulpiride and glycemic control in IDDM patients with gastroparesis. Diabetes Care. 1997;20:55\u201358.","journal-title":"Diabetes Care"},{"key":"2715_CR36","doi-asserted-by":"publisher","first-page":"288","DOI":"10.2165\/00002018-199614050-00003","volume":"14","author":"MC Mauri","year":"1996","unstructured":"Mauri MC, Bravin S, Bitetto A, Rudelli R, Invernizzi G. A risk-benefit assessment of sulpiride in the treatment of schizophrenia. Drug Saf. 1996;14:288\u201398.","journal-title":"Drug Saf"},{"key":"2715_CR37","doi-asserted-by":"publisher","first-page":"e558","DOI":"10.4088\/JCP.13f08510","volume":"74","author":"C Andrade","year":"2013","unstructured":"Andrade C. Low-dose amisulpride and elevation in serum prolactin. J Clin Psychiatry. 2013;74:e558\u201360.","journal-title":"J Clin Psychiatry"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-023-02715-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-023-02715-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-023-02715-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T13:03:59Z","timestamp":1707483839000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-023-02715-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,6]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["2715"],"URL":"https:\/\/doi.org\/10.1038\/s41433-023-02715-5","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,6]]},"assertion":[{"value":"4 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following broadly competing interest: CC, GME, JT, and TB are inventors of a submitted patent application (WO\/2021\/098996). The Universidad Nacional Aut\u00f3noma de M\u00e9xico (UNAM) and the authors JT and TB are owners of the pending patent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}